Hypercellular Proinflammatory Microenvironment Inhibits the Etoposide-Induced DNA Damage in Acute Monocytic Leukemia

Margarita I Kobyakova1, Kirill S Krasnov2,3, Olga V Krestinina2

  • 1Institute of Theoretical and Experimental Biophysics, Russian Academy of Sciences, Pushchino, Moscow Region, 142290, Russia. kobyakovami@gmail.com.

PubMed

Insights

Resistance in acute monocytic leukemia (AML-M5) to chemotherapy is a major challenge. This study reveals that a pro-inflammatory microenvironment reduces DNA damage, increasing AML cell resistance to topoisomerase inhibitors like etoposide.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Acute monocytic leukemia (AML-M5) exhibits poor patient survival due to resistance to antitumor agents.
  • AML cells possess an inflammatory phenotype, creating a pro-inflammatory microenvironment.
  • Previous studies indicated increased resistance of THP-1 AML-M5 cells to DNA topoisomerase inhibitors in simulated inflammatory conditions.

Purpose of the Study:

  • To investigate the mechanisms underlying increased resistance of AML-M5 cells to DNA topoisomerase inhibitors in a pro-inflammatory microenvironment.
  • To elucidate the role of specific signaling pathways and transcription factors in this resistance phenomenon.

Main Methods:

  • Utilized fluorescence microscopy, spectrophotometry, DNA comet assay, Western blot analysis, differential gene expression analysis, and flow cytometry.
  • Employed an in vitro model simulating a pro-inflammatory microenvironment using a three-dimensional long-term high-density cell culture of THP-1 human AML-M5 cells.

Main Results:

  • Increased resistance to etoposide in THP-1 AML-M5 cells was associated with reduced accumulation of single- and double-strand DNA breaks.
  • A diminished cellular response to DNA damage was observed in the pro-inflammatory microenvironment.
  • Pronounced activation of interferon type 1 and 2, and NF-κB/STAT signaling pathways occurred.
  • Significant suppression of Myc and E2F transcription factor activity was noted.

Conclusions:

  • Pro-inflammatory activation plays a crucial role in enhancing AML cell resistance to DNA topoisomerase inhibitor-induced death.
  • The findings offer new insights into the complex mechanisms driving therapeutic resistance in acute monocytic leukemia.

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
DNA Damage can Stall the Cell Cycle02:37

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.3K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.9K
DNA Damage Can Stall the Cell Cycle02:37

DNA Damage Can Stall the Cell Cycle

2.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K